卑詩省列治文，2018年5月28日 – Eastwood Bio-medical Canada Inc. (TSXV: EBM)（下稱”本公司”）欣然宣佈近期實現了多個重要里程碑，成功擴建生產設施和推出新產品。
Eastwood Bio-medical Canada Inc.是一家生物技術公司，致力於研究和商業化治療糖尿病、肥胖症、高血壓和癡呆症等血糖相關疾病的生物技術，也在進軍天然保健品生產業務。
本公司的股價在2018年4月低至$0.065，但2018年5月28日收於$0.215。總裁兼首席執行官Yunji Kim表示：公司管理層並不知悉公司有任何新的重要運營信息，能對股價大幅上漲的原因作出相應解釋。
但是本公司此前宣佈，本公司成功擴建了生產設施，並在獲得加拿大衛生部營銷許可批准之後，推出了新產品。加拿大衛生部是與美國食品藥品監督管理局（FDA）權利同等的加拿大政府機構。如前所述，新設施符合GMP標準並獲得了加拿大衛生部頒發的許可證，目前每天可生產300萬粒膠囊和10,000瓶包裝產品。本公司預計該設施每年可節省高達$700萬的生產成本。
Kim女士稱：”積極擴張生產工廠規模與我們長期以來建立強大企業基礎一脈相承。我們的Eleotin®品牌最初以卡爾加裡大學Julia Macfarlane糖尿病中心的尖端研究技術為基礎。國際大學和糖尿病協會研究並認可了Eleotin®。加拿大廣告標準委員會(ASC)已經准許本公司的Eleotin®品牌在加拿大用‘全球最好的’醫生推薦天然健康血糖促進產品進行市場推廣。”
Kim女士還表示：”我們對公司的擴張感到自豪和興奮。質量控制一直是我們的優先任務之一。我們首先確保自身具備世界一流的內部生產能力，採用最‘精准’的製造技術，保證生產出最優質的產品，然後以上述前提為基礎，我們才會想要挖掘產品的全部市場潛力。”
本公司本月還宣佈，在獲得加拿大衛生部批准後，上市35款新產品。過去本公司已經持續、快速地引進了科學研發的獨特健康解決方案，預計未來將繼續增加新產品。
Kim女士表示：”這對我們來說是一個激動人心的時刻。我們為我們所生產的產品感到自豪，並且期待著在未來幾個月內不斷發展。”
欲瞭解更多信息，請聯繫：
Eastwood Bio-medical Canada Inc.
總裁兼首席執行官Yunji Kim
電話: (604)-247-2100
Forward-Looking Statement:
This email contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company, including expectations and assumptions concerning TSXV approvals. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Certain factors, which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
免責聲明：此文章為NAI Interactive Ltd. 北美投資訊息有限公司有償發布，本文章內容是為了提供信息，並不構成任何管轄範圍下的證券發售或投資建議。本文章的任何內容均不應被解釋為要約、推銷或推薦購買或銷售產品或證券。
